clinical associations
Recently Published Documents


TOTAL DOCUMENTS

635
(FIVE YEARS 182)

H-INDEX

54
(FIVE YEARS 7)

Author(s):  
Claudiu Diaconu ◽  
Annie J. Lee ◽  
Kaho Onomichi ◽  
Robert L. De Jager ◽  
Claire Riley ◽  
...  

Author(s):  
Adrian Y. S. Lee ◽  
Suzanne Culican ◽  
David Campbell ◽  
Ming‐Wei Lin

Author(s):  
Zain Ul Abadin Zafar ◽  
Samina Younas ◽  
Sumera Zaib ◽  
Cemil Tunç

The main purpose of this research is to use a fractional-mathematical model including Atangana–Baleanu derivatives to explore the clinical associations and dynamical behavior of the tuberculosis. Herein, we used a lately introduced fractional operator having Mittag-Leffler kernel. The existence and inimitability problems to the relevant model were examined through the fixed-point theory. To verify the significance of the arbitrary fractional-order derivative, numerical outcomes were explored from the biological and mathematical viewpoints using the values of model parameters. The graphical simulations show the comparison of the predictor–corrector method (PCM) and Caputo method (CM) for different fractional orders and the results indicated the significant preference of PCM over CM.


2021 ◽  
Vol 8 ◽  
Author(s):  
Soraya Arzhan ◽  
Susie Q. Lew ◽  
Todd S. Ing ◽  
Antonios H. Tzamaloukas ◽  
Mark L. Unruh

The decreased ability of the kidney to regulate water and monovalent cation excretion predisposes patients with chronic kidney disease (CKD) to dysnatremias. In this report, we describe the clinical associations and methods of management of dysnatremias in this patient population by reviewing publications on hyponatremia and hypernatremia in patients with CKD not on dialysis, and those on maintenance hemodialysis or peritoneal dialysis. The prevalence of both hyponatremia and hypernatremia has been reported to be higher in patients with CKD than in the general population. Certain features of the studies analyzed, such as variation in the cut-off values of serum sodium concentration ([Na]) that define hyponatremia or hypernatremia, create comparison difficulties. Dysnatremias in patients with CKD are associated with adverse clinical conditions and mortality. Currently, investigation and treatment of dysnatremias in patients with CKD should follow clinical judgment and the guidelines for the general population. Whether azotemia allows different rates of correction of [Na] in patients with hyponatremic CKD and the methodology and outcomes of treatment of dysnatremias by renal replacement methods require further investigation. In conclusion, dysnatremias occur frequently and are associated with various comorbidities and mortality in patients with CKD. Knowledge gaps in their treatment and prevention call for further studies.


Author(s):  
Mariana Segovia-Mendoza ◽  
Margarita Isabel Palacios-Arreola ◽  
Lenin Pavón ◽  
Enrique Becerril ◽  
Karen Elizabeth Nava-Castro ◽  
...  

Public concern has emerged about the effects of endocrine disruptor compounds (EDCs) on neuropsychiatric disorders. Preclinical evidence suggests that exposure to EDCs is associated with the development of the major depressive disorder (MDD) and could result in neural degeneration. The interaction of EDCs with hormonal receptors is the best-described mechanism of their biological activity. However, the dysregulation of the hypothalamic-pituitary-gonadal adrenal axis has been reported and linked to neurological disorders. On the other hand, at a worldwide level and in Mexico, the incidence of MDD has recently been increasing. Of note, in Mexico, there are no clinical associations on blood levels of EDCs and the incidence of the MDD. Methodology: Thus, we quantified for the first time the serum levels of parent compounds of two bisphenols and four phthalates in patients with MDD. Results: The levels of di-ethyl-hexyl-phthalate (DEHP), butyl-benzyl-phthalate (BBP), di-n-butyl phthalate (DBP), and di-ethyl-phthalate (DEP), bisphenol A (BPA), and bisphenol S (BPS) were determined with a gas chromatograph-mass spectrometer. Results/ conclusion: We found significant differences between concentrations of BBP between controls and patients with MDD.


Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Maria Vittoria Cicinelli ◽  
Alessandro Rabiolo ◽  
Giovanni Montesano ◽  
Alessandro Marchese ◽  
Costanza Barresi ◽  
...  

Author(s):  
Benjamin Daines ◽  
Sanjana Rao ◽  
Omid Hosseini ◽  
Sofia Prieto ◽  
John Abdelmalek ◽  
...  

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S753-S753
Author(s):  
Karen Jacobson ◽  
Vidhya Balasubramanian ◽  
Hector F Bonilla ◽  
Martina Madrigal ◽  
Isabelle Hack ◽  
...  

Abstract Background Persistent symptoms after acute COVID-19 are being increasingly reported. To date, little is known about the cause, clinical associations, and trajectory of “Long COVID”. Methods Participants of an outpatient clinical trial of Peginterferon-Lambda as treatment for uncomplicated SARS-CoV-2 infection were invited to long term follow-up visits 4, 7, and 10 months after initial COVID-19 diagnosis. Ongoing symptoms and functional impairment measures (work productivity and activity index (WPAI), NIH toolbox smell test, 6-minute walk test) were assessed and blood samples obtained. “Long COVID” was defined as presence of 2 or more typical symptoms (fatigue, hyposmia/hypogeusia, dyspnea, cough, palpitations, memory problems, joint pain) at follow up. Associations between baseline characteristics, initial COVID-19 clinical course, and presence of “Long COVID” during follow-up were assessed using generalized estimating equations accounting for repeated measurements within individuals. Results Eighty-seven participants returned for at least one follow-up visit. At four months, 29 (34.1%) had “Long COVID”; 19 (24.7%) met criteria at 7 months and 18 (23.4%) at 10 months (Figure 1). Presence of “Long COVID” symptoms did not correlate significantly with functional impairment measures. Female gender (OR 3.01, 95% CI 1.37-6.61) and having gastrointestinal symptoms during acute COVID-19 illness (OR 5.37, 95% CI 1.02-28.18) were associated with “Long COVID” during follow-up (Figure 2). No significant associations with baseline immunologic signatures were observed. Figure 1. Alluvial plot of long term follow-up participants showing outcomes of symptoms at each visit. Figure 2. Generalized Estimating Equations Model showing associations with “Long COVID” (presence of 2+ symptoms) at month 4, 7, and 10 following acute infection using unstructured correlation matrix. Conclusion “Long COVID” was prevalent in this outpatient trial cohort and had low rates of resolution over 10 months of follow up. Female sex and gastrointestinal symptoms during acute illness were associated with “Long COVID”. Identifying modifiable risk factors associated with the development of persistent symptoms following SARS-CoV-2 infection remains a critical need. Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document